COMP <GO>
BCTX vs CELU // FORWARD P/E MULTIPLE
BriaCell Therapeutics Corp. (NASDAQ) VS. Celularity Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: BCTX 2
— CELU 0
■ METRIC PARITY
LAST: $3.04 (-8.16%) • MKT CAP: $28.9M
forward-pe
—
LAST: $0.80 (-5.79%) • MKT CAP: $27.6M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCTX VS. CELU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCTX | CELU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 24.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -51.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 1/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.4 | 38.4 | +3.00 | BCTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $28.9M | $27.6M | $1.3M | BCTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCTX REV | CELU REV | BCTX GROSS % | CELU GROSS % | BCTX FCF | CELU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $26.6M | — | 24.4% | -$28.2M | -$13.3M |
| FY 2024 | $0 | $54.2M | — | 72.4% | -$24.6M | -$6.6M |
| FY 2023 | $0 | $22.8M | — | — | -$23.7M | -$38.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCTX // BETA —
CELU // BETA —